Xeloda () vs Enhertu (fam-trastuzumab deruxtecan-nxki)
Xeloda () vs Enhertu (fam-trastuzumab deruxtecan-nxki)
Xeloda (capecitabine) is an oral chemotherapy medication typically used to treat breast cancer and colorectal cancer by interfering with the DNA synthesis of cancer cells, leading to their inability to reproduce and grow. Enhertu (fam-trastuzumab deruxtecan-nxki) is a targeted therapy known as an antibody-drug conjugate, which combines an antibody specific to the HER2 protein on certain cancer cells with a chemotherapy drug, allowing for more precise delivery of the chemotherapy to destroy the cancer cells. The choice between Xeloda and Enhertu would depend on the specific characteristics of the cancer, such as HER2 status and the stage of cancer, as well as the patient's overall health, prior treatments, and potential side effects.
Difference between Xeloda and Enhertu
Metric | Xeloda () | Enhertu (fam-trastuzumab deruxtecan-nxki) |
---|---|---|
Generic name | Capecitabine | Fam-trastuzumab deruxtecan-nxki |
Indications | Colorectal cancer, metastatic breast cancer, gastric cancer | HER2-positive breast cancer, HER2-positive gastric cancer |
Mechanism of action | Antimetabolite (thymidylate synthase inhibitor) | Antibody-drug conjugate targeting HER2 |
Brand names | Xeloda | Enhertu |
Administrative route | Oral | Intravenous |
Side effects | Hand-foot syndrome, diarrhea, nausea, fatigue | Nausea, fatigue, vomiting, alopecia, constipation |
Contraindications | Severe renal impairment, DPD deficiency | Interstitial lung disease, pneumonitis, previous severe hypersensitivity to trastuzumab |
Drug class | Chemotherapy (Antimetabolite) | Antibody-drug conjugate |
Manufacturer | Hoffmann-La Roche | Daiichi Sankyo and AstraZeneca |
Efficacy
Xeloda (Capecitabine) Efficacy in Breast Cancer
Xeloda, also known by its generic name capecitabine, is an oral chemotherapy medication that is used in the treatment of breast cancer. It is a prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in the body, where it inhibits DNA synthesis and slows the growth of cancer cells. Xeloda is particularly effective in metastatic breast cancer, either alone or in combination with other drugs. Clinical trials have demonstrated that Xeloda is effective in improving survival rates and reducing the risk of cancer progression in patients with metastatic breast cancer, especially those who have previously received anthracycline and taxane-based chemotherapy.
In the treatment of early-stage breast cancer, Xeloda has been used in combination with docetaxel after the failure of anthracycline-containing chemotherapy. Studies have shown that this combination can lead to a significant improvement in disease-free survival. Moreover, Xeloda is also used as adjuvant therapy, meaning it is given after primary treatments such as surgery to reduce the risk of cancer recurrence. Its efficacy in this context has been supported by clinical trials, which have shown a benefit in certain subgroups of breast cancer patients.
Enhertu (Fam-Trastuzumab Deruxtecan-nxki) Efficacy in Breast Cancer
Enhertu, with the active ingredient fam-trastuzumab deruxtecan-nxki, is a targeted therapy used in the treatment of breast cancer. It is an antibody-drug conjugate that combines a HER2-targeting antibody with a cytotoxic drug, allowing for the direct delivery of the chemotherapy agent to the cancer cells. Enhertu is specifically indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
The efficacy of Enhertu has been demonstrated in several clinical trials, which have shown significant improvements in overall survival and progression-free survival in patients with HER2-positive metastatic breast cancer. These trials have highlighted Enhertu's ability to provide a meaningful clinical benefit in a patient population with limited treatment options. The medication has been praised for its targeted approach, which not only enhances its effectiveness but also minimizes the impact on healthy cells, potentially reducing side effects compared to traditional chemotherapy.
Regulatory Agency Approvals
Xeloda
Enhertu
Access Xeloda or Enhertu today
If Xeloda or Enhertu are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us